CL2011000141A1 - Compuestos derivados de octahidrofenantrenona-carboxamida, moduladores del receptor glucocorticoide; composición farmaceutica que los comprende; método in vitro; y uso en el tratamiento de inflamaciones, enfermedades del snc, dermatologicas, broncopulmonares, autoinmunes, entre otras. - Google Patents
Compuestos derivados de octahidrofenantrenona-carboxamida, moduladores del receptor glucocorticoide; composición farmaceutica que los comprende; método in vitro; y uso en el tratamiento de inflamaciones, enfermedades del snc, dermatologicas, broncopulmonares, autoinmunes, entre otras.Info
- Publication number
- CL2011000141A1 CL2011000141A1 CL2011000141A CL2011000141A CL2011000141A1 CL 2011000141 A1 CL2011000141 A1 CL 2011000141A1 CL 2011000141 A CL2011000141 A CL 2011000141A CL 2011000141 A CL2011000141 A CL 2011000141A CL 2011000141 A1 CL2011000141 A1 CL 2011000141A1
- Authority
- CL
- Chile
- Prior art keywords
- glucocorticoid receptor
- treatment
- vitro method
- octahydrophenanthrenone
- bronchopulmonary
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Pyridine Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
LA PRESENTE INVENCIÓN SE DIRIGE A LOS COMPUESTOS DE FÓRMULA I O SUS SALES, QUE SON MODULADORES DEL<br /> RECEPTOR GLUCOCORTICOIDE. LA PRESENTE INVENCIÓN TAMBIÉN SE DIRIGE A LAS COMPOSICIONES FARMACÉUTICAS<br /> QUE COMPRENDEN LOS COMPUESTOS DE FÓRMULA I O SUS SALES. SE DESCRIBE ADEMÁS UN MÉTODO IN VITRO PARA<br /> PONER EN CONTACTO EL COMPUESTO DE FÓRMULA I CON EL RECEPTOR GLUCOCORTICOIDE.<br /> LOS COMPUESTOS Y SALES DE LA INVENCIÓN SON ÚTILES EN EL TRATAMIENTO DE AFECCIONES MEDIADAS POR LA<br /> ACTIVIDAD DEL RECEPTOR GLUCOCORTICOIDE, EN TRATAMIENTO DE ASMA, DERMATITIS, ENFERMEDAD INFLAMATORIA<br /> DEL INTESTINO, ENFERMEDAD DE ALZHEIMER, DEPRESIÓN MAYOR PSICÓTICA, NEUROPATÍA, RECHAZO DE<br /> TRANSPLANTE, ESCLEROSIS MÚLTIPLE, UVEÍTIS CRÓNICA, O ENFERMEDAD PULMONAR OBSTRUCTIVA CRÓNICA.<br />
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8409508P | 2008-07-28 | 2008-07-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2011000141A1 true CL2011000141A1 (es) | 2011-06-17 |
Family
ID=41037773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2011000141A CL2011000141A1 (es) | 2008-07-28 | 2011-01-21 | Compuestos derivados de octahidrofenantrenona-carboxamida, moduladores del receptor glucocorticoide; composición farmaceutica que los comprende; método in vitro; y uso en el tratamiento de inflamaciones, enfermedades del snc, dermatologicas, broncopulmonares, autoinmunes, entre otras. |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US8148409B2 (es) |
| EP (1) | EP2307375B1 (es) |
| JP (1) | JP4823397B1 (es) |
| KR (1) | KR101377860B1 (es) |
| CN (1) | CN102112446B (es) |
| AP (1) | AP2744A (es) |
| AR (1) | AR072535A1 (es) |
| AU (1) | AU2009278029B2 (es) |
| BR (1) | BRPI0917212A2 (es) |
| CA (1) | CA2729578C (es) |
| CL (1) | CL2011000141A1 (es) |
| CO (1) | CO6290761A2 (es) |
| CR (1) | CR20110012A (es) |
| CU (1) | CU23983B1 (es) |
| DK (1) | DK2307375T3 (es) |
| DO (1) | DOP2011000029A (es) |
| EA (1) | EA018024B1 (es) |
| EC (1) | ECSP11010795A (es) |
| ES (1) | ES2527137T3 (es) |
| GE (1) | GEP20125640B (es) |
| GT (1) | GT201100026A (es) |
| HR (1) | HRP20150021T1 (es) |
| IL (1) | IL210492A (es) |
| MA (1) | MA32512B1 (es) |
| MX (1) | MX2011001053A (es) |
| NI (1) | NI201100028A (es) |
| NZ (1) | NZ590559A (es) |
| PE (1) | PE20110559A1 (es) |
| PL (1) | PL2307375T3 (es) |
| PT (1) | PT2307375E (es) |
| RS (1) | RS53747B1 (es) |
| SI (1) | SI2307375T1 (es) |
| SV (1) | SV2011003821A (es) |
| TW (1) | TWI374878B (es) |
| UA (1) | UA99198C2 (es) |
| UY (1) | UY32011A (es) |
| WO (1) | WO2010013158A1 (es) |
| ZA (1) | ZA201101520B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012125797A1 (en) * | 2011-03-15 | 2012-09-20 | Abbott Laboratories | Nuclear hormone receptor modulators |
| TW201422590A (zh) | 2012-09-07 | 2014-06-16 | Abbvie Inc | 雜環核激素受體調節劑 |
| WO2014094357A1 (en) | 2012-12-21 | 2014-06-26 | Abbvie Inc. | Heterocyclic nuclear hormone receptor modulators |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA01011018A (es) | 1999-04-30 | 2002-05-06 | Pfizer Prod Inc | Moduladores del receptor glucocorticoide. |
| HUP0202283A3 (en) | 1999-07-30 | 2003-10-28 | Eisai Co Ltd | Process for the preparation of basic antibiotic-inorganic acid addition salts and intermediate oxalates |
| ES2262612T3 (es) * | 2000-10-28 | 2006-12-01 | Pfizer Products Inc. | Moduladpres del receptor de glucocorticoides. |
| ES2246292T3 (es) * | 2000-10-30 | 2006-02-16 | Pfizer Products Inc. | Moduladores de receptor glucocorticoide. |
| JP4503436B2 (ja) * | 2002-07-08 | 2010-07-14 | ファイザー・プロダクツ・インク | 糖質コルチコイド受容体のモジュレーター |
| AU2006206458B2 (en) | 2005-01-19 | 2012-10-25 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| GB0613836D0 (en) | 2006-07-13 | 2006-08-23 | Univ Greenwich | New medical use of triazine derivatives |
| ATE540041T1 (de) | 2006-11-21 | 2012-01-15 | Rigel Pharmaceuticals Inc | Prodrug-salze von 2,4-pyrimidindiaminverbindungen und anwendungen davon |
| BRPI0719937A2 (pt) | 2006-12-05 | 2014-03-11 | Neurogesx Inc | Pró-fármacos e métodos de fazer e de usar os mesmos |
| HRP20110702T1 (hr) * | 2007-02-02 | 2011-10-31 | Pfizer Products Inc. | Triciklički spojevi i njihova uporaba kao modulatora glukokortikoidnih receptora |
| EP2114888B1 (en) * | 2007-02-02 | 2010-11-10 | Pfizer Products Inc. | Tricyclic compounds and their use as glucocorticoid receptor modulators |
-
2009
- 2009-07-14 ES ES09786592.7T patent/ES2527137T3/es active Active
- 2009-07-14 MX MX2011001053A patent/MX2011001053A/es active IP Right Grant
- 2009-07-14 PE PE2011000098A patent/PE20110559A1/es not_active Application Discontinuation
- 2009-07-14 UA UAA201100440A patent/UA99198C2/ru unknown
- 2009-07-14 SI SI200931100T patent/SI2307375T1/sl unknown
- 2009-07-14 PL PL09786592T patent/PL2307375T3/pl unknown
- 2009-07-14 JP JP2011520622A patent/JP4823397B1/ja not_active Expired - Fee Related
- 2009-07-14 EA EA201100080A patent/EA018024B1/ru not_active IP Right Cessation
- 2009-07-14 AU AU2009278029A patent/AU2009278029B2/en not_active Ceased
- 2009-07-14 AP AP2011005562A patent/AP2744A/xx active
- 2009-07-14 RS RS20150019A patent/RS53747B1/sr unknown
- 2009-07-14 WO PCT/IB2009/053044 patent/WO2010013158A1/en not_active Ceased
- 2009-07-14 KR KR1020117002134A patent/KR101377860B1/ko not_active Expired - Fee Related
- 2009-07-14 NZ NZ590559A patent/NZ590559A/en not_active IP Right Cessation
- 2009-07-14 CN CN200980129538XA patent/CN102112446B/zh not_active Expired - Fee Related
- 2009-07-14 PT PT97865927T patent/PT2307375E/pt unknown
- 2009-07-14 DK DK09786592.7T patent/DK2307375T3/en active
- 2009-07-14 GE GEAP200912074A patent/GEP20125640B/en unknown
- 2009-07-14 EP EP09786592.7A patent/EP2307375B1/en active Active
- 2009-07-14 HR HRP20150021AT patent/HRP20150021T1/hr unknown
- 2009-07-14 BR BRPI0917212A patent/BRPI0917212A2/pt not_active IP Right Cessation
- 2009-07-14 CA CA2729578A patent/CA2729578C/en not_active Expired - Fee Related
- 2009-07-20 US US12/505,932 patent/US8148409B2/en not_active Expired - Fee Related
- 2009-07-27 AR ARP090102852A patent/AR072535A1/es unknown
- 2009-07-27 TW TW098125265A patent/TWI374878B/zh not_active IP Right Cessation
- 2009-07-28 UY UY0001032011A patent/UY32011A/es not_active Application Discontinuation
-
2011
- 2011-01-06 IL IL210492A patent/IL210492A/en not_active IP Right Cessation
- 2011-01-10 CR CR20110012A patent/CR20110012A/es unknown
- 2011-01-21 CL CL2011000141A patent/CL2011000141A1/es unknown
- 2011-01-26 NI NI201100028A patent/NI201100028A/es unknown
- 2011-01-27 DO DO2011000029A patent/DOP2011000029A/es unknown
- 2011-01-27 GT GT201100026A patent/GT201100026A/es unknown
- 2011-01-27 CO CO11009253A patent/CO6290761A2/es active IP Right Grant
- 2011-01-28 CU CU2011000020A patent/CU23983B1/es active IP Right Grant
- 2011-01-28 MA MA33568A patent/MA32512B1/fr unknown
- 2011-01-28 SV SV2011003821A patent/SV2011003821A/es unknown
- 2011-01-28 EC EC2011010795A patent/ECSP11010795A/es unknown
- 2011-02-25 ZA ZA2011/01520A patent/ZA201101520B/en unknown
-
2012
- 2012-02-27 US US13/406,446 patent/US8552035B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR10538A (es) | Moduladores del metabolismo y tratamiento de los trastornos metabolicos | |
| PE20151144A1 (es) | Moduladores de la orphan receptor gamma retinoides relacionados (ror - gamma) para uso en el tratamiento de las enfermedades autoinmunes e inflamatorias | |
| UY30287A1 (es) | Dihidrotienopirimidinas para el tratamiento de enfermedades inflamatorias | |
| DOP2006000169A (es) | Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| UY31496A1 (es) | Agonistas novedosos de los receptores de glucocorticoides | |
| CR10700A (es) | Derivados de sulfonamida | |
| CU20090184A7 (es) | Compuestos amino-heterocíclicos | |
| ECSP12011983A (es) | Moduladores alostéricos positivos de receptores m1 de la quinolina amida | |
| UY31471A1 (es) | Derivados bis-(sulfonilamino) en terapia 066 | |
| UY32259A (es) | Nuevos compuestos de hidroxiareno, preparados farmaceuticos que los contienen y aplicaciones | |
| CR8649A (es) | Derivados de formamidina para el tratamiento de enfermedades | |
| ECSP088099A (es) | Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas | |
| PA8622001A1 (es) | Derivados de sulfonamida para el tratamiento de enfermedades | |
| AR072085A1 (es) | Compuestos triciclicos, metodos para su preparacion, composicion farma-ceutica que los comprende y su uso en el tratamiento de enfermedades me-diadas por la actividad de las proteinas quinasas | |
| UY32004A (es) | Derivados de carbamatos de alquiltiazoles, su preparación y su aplicación en terapéutica | |
| CL2010001566A1 (es) | Compuesto derivado de piperidinilo, modulador de la actividad de los receptores de la quimiocina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias, alergicas, autoinmune. | |
| CL2011000141A1 (es) | Compuestos derivados de octahidrofenantrenona-carboxamida, moduladores del receptor glucocorticoide; composición farmaceutica que los comprende; método in vitro; y uso en el tratamiento de inflamaciones, enfermedades del snc, dermatologicas, broncopulmonares, autoinmunes, entre otras. | |
| AR077958A1 (es) | Quinoxalinonas antagonistas de la hepcidina | |
| AR071278A1 (es) | Derivados de alfa -aminoamida utiles en el tratamiento de los trastornos psiquiatricos, y formulaciones farmaceuticas que los contienen | |
| GEP20135804B (en) | Glucocorticoid receptor agonist comprising novel 1,2,3,4-tetrahydroquinoxaline derivative containing phenyl group having sulfonic acid ester introduced therein as substituent | |
| CO6280529A2 (es) | DERIVADOS DE AMIDA AROMÁTICOS DE ÁCIDO PENTANOICO COMO MODULADORES DE γ - SECRETOSA | |
| CO6280527A2 (es) | Derivados de amina aromáticos de ácido pentanoico como moduladores de gama secretasa | |
| GT200500214A (es) | Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y análogos relacionados como inhibidores de la caseína cinasa epsilon | |
| PE20131342A1 (es) | Nuevos derivados dihidrobenzoxatiazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| GT200500059A (es) | Compuestos para el tratamiento de enfermedades |